AMENDMENT NO. 4 TO AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTLogicBio Therapeutics, Inc. • August 10th, 2020 • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 4 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment No. 4”) is made as of April 29, 2020 (“Amendment No. 4 Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, and amended again by that certain Amendment No. 2 dated June 3, 2019, and amended again by that certain Amendment No. 3 dated January 29, 2020, to Amended and Restated Exclusive (Equity) Agreement (the “Original Agreement,” and as amended by this Amendment No. 4, the “Agreement”).
